FTP 637
Alternative Names: FTP-637Latest Information Update: 28 Mar 2024
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antineoplastics; Antipsoriatics; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
- No development reported Psoriasis
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Psoriasis(Combination therapy, In volunteers) in China (PO, Suspension)
- 17 Feb 2021 Phase-I clinical trials in Psoriasis (In volunteers) in China (PO) (ACTRN12621000011886)
- 11 Jan 2021 Haisco Pharmaceutical plans a phase I trial for Psoriasis and Autoimmune disorders (Combination therapy) in Australia (ACTRN12621000011886p)